Key result
Kidney transplantation is linked to a ~6-point reduction in hypertension prevalence at 1 year.
Why the study?
Arterial hypertension is the main cause of cardiovascular morbidity, mortality, and progressive graft dysfunction after kidney transplantation, and recipients exhibit varying blood pressure across home, office, and ambulatory monitoring.
How does kidney transplantation affect blood pressure control, ambulatory blood pressure phenotypes, and cardiovascular complications over 12 months of follow-up?
Cohort (n=50)
How does kidney transplantation affect blood pressure control, ambulatory blood pressure phenotypes, and cardiovascular complications over 12 months of follow-up?
Answers are grounded in this paper and cite their sources.
Kidney transplantation improves blood pressure dipping patterns, reduces antihypertensive medication burden, and improves metabolic parameters at 1 year, though notable cardiovascular event risk persists.
Background and Aims Arterial hypertension (AH) represents the main cause of cardiovascular (CV) morbidity and mortality in the period after kidney transplantation (KT). It is an independent risk factor for atherosclerosis and related CV complications including concentric left ventricular hypertrophy, heart failure, coronary artery disease and overall CV mortality. Inadequate hypertension control in the grafts leads to glomerulosclerosis, intraglomerular hypertension, proteinuria and it is a non-immunological cause of progressive graft dysfunction. KT recipients exhibit varying blood pressure (BP) measured at home, in the doctor's office and through systematic BP monitoring methods including ambulatory BP monitoring (ABPM). Method We present prospective study of CV risk factors and ABPM in cohort of patients (n = 50) transplanted from deceased (80%) and living donors (20%) during the period from January 2022 to February 2024. Follow up was 12 months after KT. Results Prior to KT 92% of patients were hypertensive, which decreased to 86% within the 1. year post-KT. Positive trends were noted in the prevalence of abnormal AH phenotypes with non-dippers and reverse dippers reduced by 8% and 4%, respectively, and normal dipping pattern restored in 12% of patients by the end of the 1. year. There was a marked decrease (35%) in the number of AH medications required, particularly in patients on triple and more AH regimens. The incidence of acute coronary syndrome within the 1. year post-KT was 8%, including STEMI, NSTEMI and unstable angina pectoris, CV events such as paroxysmal atrial fibrillation (6%), hypertensive emergencies (6%) and strokes (4%) were recorded. Graft loss occurred in 6% of patients, mortality was 6% (COVID-19, stroke, MODS). Additional findings included improvements in eGF (P = 0.022) and proteinuria (P = 0.304) comparing results from 3rd month post-KT and 12th month post-KT, and improvements in anaemia (P = 0.00000001), hyperuricemia (P = 0.024) and hyperparathyroidism (P = 0.00002) comparing results prior to KT and from 12th month post-KT. Conclusion KT significantly improves BP control, metabolic profiles and echocardiographic findings in the 1. year. Long-term strategies to minimize CV risk should include maintaining BP ˂140 mmHg, early intervention for dyslipidaemia and glucose metabolism disorders, obesity prevention and individualized immunosuppressive therapy.
No takes yet. Share an insight, caveat, or question.
Javorkova et al. (2025) conducted a cohort in Arterial hypertension and cardiovascular complications after kidney transplantation (n=50). Kidney transplantation vs. Pre-transplant baseline status was evaluated on Prevalence of arterial hypertension at 1 year post-kidney transplantation. Kidney transplantation reduced hypertension prevalence from 92% to 86% and antihypertensive medication need by 35% at 1 year, with an 8% incidence of acute coronary syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: